drugset
drugset / Trial / NCT01704378

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

NCT01704378 ↗

Phase 4 Completed 89 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.

Timeline

Start
2001-04-18
Primary completion
2003-03-14
Completion
2003-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus